1
Jupiter biotech awarded $4.5M SBIR grant
Myosin Therapeutics, a Jupiter-based biotechnology company developing novel therapies for aggressive cancers, announced it has been awarded a $4.5 million Phase II award from the National Cancer Institute’s Small Business Innovation Research (SBIR) program.
The funding will support Myosin Therapeutic’s Phase I STAR-GBM dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with newly diagnosed, MGMT unmethylated glioblastoma. Glioblastoma remains among the most lethal cancers, with median survival measured in months. MT-125 targets non-muscle myosin II, a critical driver of tumor cell invasion, proliferation and treatment resistance, representing a novel therapeutic approach that is distinct from existing standards of care, the company said.
The NCI SBIR program is one of the most competitive federal funding mechanisms for cancer-focused innovation, and Bridge Awards, which require that matching funds from private capital be raised first, are reserved for companies with promising, later-stage projects that have already demonstrated significant technical progress and the potential to attract substantial private investment…